[DOI] [PMC free article] [PubMed] [Google Scholar] 107.The Glucagon-like peptide-1 receptor agonist, exendin-4, ameliorated gastrointestinal dysfunction in the Wistar Kyoto rat model of Irritable Bowel Syndrome
This is similar to semaglutide's effect on food consumption in that we see people stop eating sooner, which is how people lose weight on semaglutide, he says
doi:10.1186/bcr3346 Takada, K., Melnikov, V
Important Safety Information for GLP-1 Treatments Compounded medications are legally prescribed under federal law but are not FDA-approved and have not undergone FDA review for safety, effectiveness, or manufacturing quality
And importantly, this should not be framed as an anti-GLP-1 conversation